Individualized Treatment of Hbeag-Negative Chronic Hepatitis B Using Pegylated Interferon-α2A as First-Line and Week-12 HBV Dna/Hbsag Stopping Rule: A Cost-Effectiveness Analysis

Abstract

Background

Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is the most frequent and difficult-to-treat viral hepatitis worldwide. HBV DNA and hepatitis B surface antigen (HBsAg) serum levels, which help the early identification of non-responders to pegylated interferon (PEG-IFN), prompt more flexible individualized therapeutic strategies exploiting the benefits of both PEG-IFN and nucleoside/nucleotide analogues (NAs). We assessed the cost-effectiveness of week-12 HBV DNA/ HBsAg stopping rule for early interruption and switch to currently most effective NA treatments (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]).

Methods

A decision-analytic Markov model was developed in the following health-related states: CHB, compensated cirrhosis (CC) and decompensated cirrhosis, hepatocellular carcinoma, liver transplant, post-liver transplant, death, virological response, relapse and HBsAg clearance. Simulated strategies included: ETV/TDF in CHB; ETV/TDF delayed until CC; first-line PEG-IFN followed by switch to ETV/TDF for either patients meeting the week-12 stopping rule or week-48 null-responders/relapsers; and first-line PEG-IFN followed by switch to ETV/TDF delayed until CC. ETV and TDF were considered alternatively for a total of eight strategies. A lifetime simulation horizon was applied.

Results

Early treatment strategies using NAs with or without first-line PEG-IFN provided the highest results (approximately 22 life-years and 15 quality-adjusted life years [QALYs]). Delayed treatments until cirrhosis development resulted in poorer outcomes. The average per-patient lifetime costs ranged from €33,500 (TDF in CC) to €68,900 (TDF in CHB). Costs using ETV were 20–50% higher. First-line PEG-IFN strategies ranged from dominant (that is, more effective and less costly) to highly cost-effective, although differences in QALYs were always very narrow.

Conclusions

The cost-effectiveness of antiviral therapy of HBeAg-negative CHB could be improved significantly using first-line PEG-IFN followed by a switch to NAs in either patients meeting the week-12 HBV DNA/HBsAg stopping rule or week-48 non-responders/relapsers.

References

European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.

Kim

W.R.

Epidemiology of hepatitis B in the United States. Hepatology 2009; 49 Suppl 5: S28–S34.

Kwon

, Lok

A.S.

Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 275–284.

Bonino

, Rosina

, Rizzetto

Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268–1273.

Liaw

Y.F.

, Brunetto

M.R.

, Hadziyannis

The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010; 15 Suppl 3: 25–33.

Brunetto

M.R.

, Oliveri

, Coco

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263–270.

Marcellin

, Lau

G.K.

, Bonino

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–1217.

Brunetto

M.R.

, Moriconi

, Bonino

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141–1150.

Moucari

, Mackiewicz

, Lada

Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151–1157.

10.

Rijckborst

, Hansen

B.E.

, Cakaloglu

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454–461.

11.

Marcellin

, Piratvisuth

, Brunetto

On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment and subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alfa-2a (40 kD) (PEGASYS). 20th Conference of the Asian Pacific Association for the Study of the Liver. 25–28 March 2010, Beijing, China. (Accessed 21 June 2013.) Available from http://www.natap.org/2009/APASL/APASL_05.htm.

12.

Lai

C.L.

, Shouval

, Lok

A.S.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011–1020.

13.

Marcellin

, Heathcote

E.J.

, Buti

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442–2455.

14.

Rijckborst

, Hansen

B.E.

, Ferenci

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006–1011.

15.

Rijckborst

, Borg

M.J.

, Cakaloglu

A randomized trial of peginterferon alfa-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 1762–1769.

16.

Lampertico

, Vigano

, Di Costanzo

Extended (2 years) treatment with peginterferon alfa-2a (40 kD) improves virologic response rates in genotype D patients with HBeAg negative chronic hepatitis B. J Hepatol 2010; 52: S45.

17.

Marcellin

, Chen

X.Y.

, Curescu

Early HBsAg decline as a predictor of HBsAg clearance in ‘real life': results of the S-Collate cohort study in 683 HBeAg-negative patients. 22nd Annual Meeting of the Asian Pacific Association for the Study of the Liver. 16–19 February 2012, Taipei, Taiwan. (Accessed 21 June 2013.) Available from http://www.natap.org/2012/APASL/APASL_31.htm.

18.

Lampertico

, Vigano

, Soffredini

Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B: a 4-year field practice, multicenter study. 47th Annual Meeting of the European Association for the Study of the Liver. 18–22 April 2012, Barcelona, Spain. (Accessed 21 June 2013.) Available from http://www.natap.org/2012/EASL/EASL_86.htm.

19.

Lampertico

, Vigano

, Soffredini

Tenofovir monotherapy for naive patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months. 47th Annual Meeting of the European Association for the Study of the Liver. 18–22 April 2012, Barcelona, Spain. (Accessed 21 June 2013.) Available from http://www.natap.org/2012/EASL/EASL_87.htm.

20.

Marcellin

, Piratvisuth

, Brunetto

HBsAg decline appears to predict clearance- increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a ± lamivudine: results of 5-year post-treatment follow-up. 44th Annual Meeting of the European Association for the Study of the Liver. 22–24 April 2009, Copenhagen, Denmark. (Accessed 21 June 2013.) Available from http://www.natap.org/2009/EASL/EASL_56.htm.

21.

Kim

W.R.

, Veenstra

D.L.

, Iloeje

U.H.

The natural history of chronic hepatitis B infection: a new computer simulation model to incorporate events subsequent to HBeAg seroconversion. Digestive Disease Week. 14–19 May 2005, Chicago, IL, USA.

22.

Veenstra

D.L.

, Spackman

D.E.

, Bisceglie

, Kowdley

K.V.

, Gish

R.G.

Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 2008; 12: 1240–1252.

23.

Fattovich

, Bortolotti

, Donato

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335–352.

24.

Papatheodoridis

G.V.

, Lampertico

, Manolakopoulos

, Lok

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348–356.

25.

Papatheodoridis

G.V.

, Manolakopoulos

, Touloumi

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60: 1109–1116.

26.

Colombo

G.L.

, Gaeta

G.B.

, Viganò

, Di Matteo

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011; 3: 37–46.

27.

Farmadati Italia. Compendio Farmaceutico Plus [Italian Drug Formulary]. Banca dati del Farmaco e Parafarmaco e dei Dispositivi Medici Ospedalieri. (Accessed 3 June 2013.) Available from http://www.farmadati.it/.

28.

Gazzetta Ufficiale [Official Gazette of the Italian Republic] Agenzia Italiana Del Farmaco [Italian Drug Agency]. Determinazione July 3 2006. Elenco dei medicinali di classe a) rimborsabili dal Servizio sanitario nazionale (SSN) ai sensi dell'articolo 48, comma 5, lettera c), del decreto-legge 30 settembre 2003, n. 269, convertito, con modificazioni, nella legge 24 novembre 2006, n. 326. GU number 156, Suppl 161. (Updated 7 July 2006. Accessed 28 June 2013.) Available from http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2006-07-07&atto.codiceRedazionale=06A06166&elenco30giorni=false.

29.

Gazzetta Ufficiale [Official Gazette of the Italian Republic] Agenzia Italiana Del Farmaco [Italian Drug Agency]. Determinazione September 27 2006. Manovra per il governo della spesa farmaceutica convenzionata e non convenzionata. GU number 227. (Updated 29 September 2006. Accessed 28 June 2013.) Available from http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2006-09-29&atto.codiceRedazionale=06A08826&elenco30giorni=false.

30.

AISF (Associazione Italiana per lo Studio del Fegato). Libro Bianco AISF 2011 – proposta per un piano nazionale per le malattie epatiche. (Updated 30 April 2011. Accessed 28 June 28 2013.) Available from http://www.webaisf.org/img/newrelease/LIBRO-BIANCO-AISF-2011.pdf.

31.

Munari

L.M.

, Picciotto

A.A.

Recombinant interferon a-2b therapy of chronic hepatitis C in Italy: an economic analysis. Trends Exp Clin Med 1996; 6: 347–353.

32.

Gazzetta Ufficiale [Official Gazette of the Italian Republic] Nomenclatore Tariffario Specialistico [Italian outpatient tariff list]. Decreto Ministeriale 22 July 1996. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio sanitario nazionale e relative tariffe. GU number 216, Suppl 150. (Updated 14 September 1996. Accessed 21 June 2013.) Available from http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=1996-09-14&atto.codiceRedazionale=096A5753&elenco30giorni=false.

33.

Levy

A.R.

, Kowdley

K.V.

, Iloeje

The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008; 11: 527–538.

34.

Torrance

G.W.

Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 1–30.

35.

Briggs

Handling uncertainty in economic evaluations and presenting the results. In Drummond

, McGuire

(Editors). Economic evaluation in health care. Oxford: Oxford University Press 2001; pp. 172–214.

36.

Arnold

, Yuan

, Iloeje

, Cook

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy 2008; 6: 231–246.

37.

Buti

, Brosa

, Casado

M.A.

, Rueda

, Esteban

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51: 640–646.

38.

Dakin

, Bentley

, Dusheiko

Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health 2010; 13: 922–933.

39.

Lui

Y.Y.

, Tsoi

K.K.

, Wong

V.W.

Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther 2010; 15: 145–155.

40.

Liu

, Cipriano

L.E.

, Holodniy

, Owens

D.K.

, Goldhaber-Fiebert

J.D.

New protease inhibitors for the treatment of chronic hepatitis C: a cost effectiveness analysis. Ann Intern Med 2012; 156: 279–290.

41.

Brunetto

M.R.

, Marcellin

, Cherubini

Response to PEG-IFN alfa-2a in HBeAg negative CHB: baseline and on treatment kinetics of HBsAg serum levels vary according to HBV genotype. Hepatology 2011; 54 Suppl 4: 1059A.